Regence – Commercial: Genetic Testing
May 10, 2021Genetic Testing: effective May 1, 2021
- Genetic Testing for Hereditary Breast and Ovarian Cancer and LiFraumeni Syndrome (#02)
- Added medical necessity criterion for germline BRCA1/2 testing if tumor testing indicates that a variant is present in the tumor tissue
- Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer (#42)
- Added the use of the Breast Cancer Index for making decisions regarding extended endocrine therapy (beyond five years)
- Made additional minor edits for clarity
The source page for this article has moved or has expired.
Please visit the Billing Beat News or Beyond Billing Blog for relevant information or search our site for specific information related to this article.
Original source URL:
https://beonbrand.getbynder.com/m/75628f3dd274884f/original/2021-May-Bulletin.pdf